English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Portal vein thrombosis (PVT) increases the surgical complexity of living donor liver transplantation (LDLT) and pre-transplant complete PVT is associated with decreased 1-year patient survival. Increased experience in the field of liver transplantation (LT) and refinements of the surgical techniques have led to successful outcomes even in recipients with complete PVT. Such techniques include thrombectomy of the native portal vein, extensive thromboendovenectomy up to the splenomesenteric confluence, venous conduit interposition and portocaval hemitransposition. In this report, we describe the outcome after LDLT using an expanded polytetrafluoroethylene (ePTFE) conduit from superior mesenteric vein (SMV) for portal inflow in patients with complete PVT. Materials and Methods: From 10 September 2002 to 31 May 2017, 900 LT surgeries were performed at China Medical University Hospital, Taiwan. The database of the 30 recipients (3.3%) that had pre-LT PVT was retrospectively analysed. Portal vein thrombectomy was done in 27 patients, whereas a ePTFE graft was used as a jump graft from the SMV to establish portal flow in three LDLT recipients (n=3). Results: ePTFE jump graft was used to establish portal inflow in three LDLT recipients (M:F, 3:0; mean age, 53 years). The first patient in this series did not receive any anticoagulation. At 14 month post-LDLT the ePTFE conduit was found to be thrombosed with multiple collaterals. However, the liver function tests were normal. The patient developed one episode of sepsis from which he completely recovered, and continues to have normal liver function till the latest follow up. The remaining 2 patients in this series received warfarin as anticoagulation therapy, with a dose of 3.5 mg per day. The latest imaging studies in both the recipients revealed a patent ePTFE conduit with satisfactory portal flow and normal postoperative liver function. Conclusions: The portal inflow can be successfully established in LDLT for recipients with pre-LT complete PVT without increasing the mortality risk. However, anticoagulation with warfarin must be instituted to avoid thrombotic occlusion of the ePTFE graft.

surgery, gastroenterology and oncology

Reconstruction of the Portal Vein with Expanded Polytetrafluoroethylene Jump Graft in Living Donor Liver Transplantation Recipients with Complete Portal Vein Thrombosis: A Feasible and Safe Alternative